Education
About Us
Working with TipRanks
Follow Us
CSL Limited (CSLLY)
OTHER OTC:CSLLY
CSLLY Stock Chart & Stats
$58.68
$0.39(0.44%)
At close: 4:00 PM EST
$58.68
$0.39(0.44%)
Day’s Range― - ―
52-Week Range$56.46 - $89.51
Previous CloseN/A
Volume10.38K
Average Volume (3M)1.91K
Market Cap
$56.63B
Enterprise Value$9.48B
Total Cash (Recent Filing)$2.16B
Total Debt (Recent Filing)$11.65B
Price to Earnings (P/E)18.7
Beta0.39
Next Earnings
Feb 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.37%
Share Statistics
EPS (TTM)1.03
Shares Outstanding970,302,800
10 Day Avg. Volume0
30 Day Avg. Volume1,912
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)3.97
Price to Sales (P/S)4.97
P/FCF Ratio30.14
Enterprise Value/Market Cap0.17
Enterprise Value/Revenue0.61
Enterprise Value/Gross Profit1.24
Enterprise Value/Ebitda1.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CSL News
CSLLY FAQ
What was CSL Limited’s price range in the past 12 months?
CSL Limited lowest stock price was $56.46 and its highest was $89.50 in the past 12 months.
What is CSL Limited’s market cap?
CSL Limited’s market cap is $56.63B.
When is CSL Limited’s upcoming earnings report date?
CSL Limited’s upcoming earnings report date is Feb 10, 2026 which is in 48 days.
How were CSL Limited’s earnings last quarter?
CSL Limited released its earnings results on Aug 18, 2025. The company reported $1.028 earnings per share for the quarter, beating the consensus estimate of N/A by $1.028.
Is CSL Limited overvalued?
According to Wall Street analysts CSL Limited’s price is currently Overvalued.
Does CSL Limited pay dividends?
CSL Limited pays a Semiannually dividend of $0.76 which represents an annual dividend yield of 2.37%. See more information on CSL Limited dividends here
What is CSL Limited’s EPS estimate?
CSL Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CSL Limited have?
CSL Limited has 970,302,800 shares outstanding.
What happened to CSL Limited’s price movement after its last earnings report?
CSL Limited reported an EPS of $1.028 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -17.176%.
Which hedge fund is a major shareholder of CSL Limited?
Currently, no hedge funds are holding shares in CSLLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.06%
12-Months-Change
Fundamentals
Return on Equity
16.36%
Trailing 12-Months
Asset Growth
3.63%
Trailing 12-Months
Company Description
CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CSLLY Company Deck
CSLLY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
CSL demonstrated solid revenue and profit growth, introduced transformative corporate strategies including a demerger and share buyback, and achieved operational efficiencies. However, challenges in Seqirus revenue growth, impacts from U.S. healthcare reforms, and the need for significant cost reductions in R&D and plasma centers indicate some operational pressures.View all CSLLY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---